39 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
11 Dec 23
Cassava Sciences Appoints
4:18pm
of Directors, effective immediately.
Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted in 14 new drug approvals
8-K
EX-99.1
SAVA
Cassava Sciences Inc
27 Oct 22
Cassava Sciences Announces Expansion of Leadership Team
4:03pm
Exhibit 99.1
Cassava Sciences Announces Expansion of Leadership Team
Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel … : SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the expansion of its leadership team with the appointment
8-K
EX-99.1
v9x 5104w12o5o81z
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
xini9uskfsc9h6p9ic
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-10.1
95fnqxd5m6xzitmpl
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
pee5mj
11 Oct 18
Pain Therapeutics Announces Appointment of
4:12pm